Open AccessNucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors
Author(s) -
Sunee Sirivichayakul,
Kiat Ruxrungtham,
Chaiwat Ungsedhapand,
Wichai Techasathit,
Sasiwimol Ubolyam,
Theshinee Chuenyam,
Sean Emery,
David A. Cooper,
Joep M. A. Lange,
Praphan Phanuphak
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200309050-00007
Subject(s) - didanosine , stavudine , zidovudine , lamivudine , virology , resistance mutation , nucleoside analogue , abacavir , reverse transcriptase inhibitor , nucleoside , reverse transcriptase , nucleoside reverse transcriptase inhibitor , biology , medicine , sida , viral load , viral disease , virus , antiretroviral therapy , polymerase chain reaction , hepatitis b virus , gene , biochemistry
To investigate genotypic drug resistance in HIV-1 subtype A/E infection associated with failure of double/triple-nucleoside reverse transcriptase (RT) inhibitor therapy.